recent
middl
east
respiratori
syndrom
coronaviru
merscov
outbreak
pose
seriou
threat
public
health
summar
recent
advanc
identifi
human
neutral
monoclon
antibodi
mab
merscov
describ
mechan
action
analyz
potenti
treatment
merscov
infect
septemb
novel
human
coronaviru
middl
east
respiratori
syndrom
mer
coronaviru
merscov
isol
saudi
arabian
patient
suffer
sarslik
diseas
character
fever
cough
short
breath
patient
later
die
respiratori
renal
failur
peopl
diagnos
merscov
infect
develop
sever
acut
respiratori
ill
novemb
laboratoryconfirm
case
merscov
infect
report
world
health
organ
includ
least
relat
death
http
wwwwhointcsr
outbreak
merscov
pose
seriou
threat
global
public
health
highlight
urgent
need
develop
effect
therapeut
prophylact
agent
treat
prevent
merscov
infect
therapeut
modal
base
monoclon
antibodi
mab
shown
clinic
success
treatment
mani
diseas
therapeut
potenti
antibodi
target
coronavirus
well
recogn
sar
outbreak
review
summar
recent
progress
identifi
human
neutral
mab
merscov
describ
mechan
action
analyz
potenti
therapi
prophylaxi
mer
also
discuss
futur
direct
toward
develop
strategi
rapid
develop
antibodybas
antivir
combat
emerg
virus
diseas
outbreak
set
coronavirus
larg
famili
virus
typic
infect
respiratori
gastrointestin
tract
mammal
base
observ
electron
microscopi
name
solar
coronalik
surfac
project
creat
viral
spike
glycoprotein
first
two
coronavirus
infect
human
identifi
nasal
caviti
patient
present
common
cold
found
caus
mild
moder
upper
respiratori
tract
ill
result
coronavirus
consid
rel
harmless
human
howev
winter
clinician
recogn
new
deadli
coronaviru
strain
abl
infect
upper
lower
respiratori
tract
caus
sever
acut
respiratori
syndrom
sar
coronaviru
subsequ
name
sarscov
rapidli
spread
around
world
caus
worldwid
outbreak
confirm
case
includ
death
http
sar
epidem
contain
known
case
sarscov
infect
report
sinc
two
human
coronavirus
discov
coronavirus
like
common
cold
virus
circul
worldwid
gener
caus
rel
mild
respiratori
symptom
howev
threat
coronavirus
disappear
novel
coronaviru
merscov
identifi
human
infect
result
higher
mortal
rate
sarscov
similar
sarscov
merscov
caus
atyp
pneumonia
acut
respiratori
distress
syndrom
potenti
renal
failur
infect
individu
merscov
case
report
twenti
countri
includ
saudi
arabia
qatar
egypt
unit
arab
emir
franc
unit
kingdom
unit
state
shown
spread
peopl
close
contact
despit
share
sever
clinic
epidemiolog
featur
common
sarscov
two
coronavirus
still
distinguish
merscov
lineag
c
betacoronaviru
sarscov
lineag
b
betacoronaviru
merscov
phylogenet
distinct
human
coronaviru
includ
sarscov
relat
bat
coronavirus
importantli
merscov
use
dipeptidyl
also
name
receptor
surfac
human
cell
sarscov
use
angiotensinconvert
enzym
cellular
receptor
differ
receptor
bind
merscov
sarscov
may
reflect
abil
prefer
infect
cell
wide
express
noncili
bronchial
epithelium
epitheli
cell
kidney
small
intestin
liver
parotid
gland
even
testi
prostat
wide
distribut
may
explain
divers
clinic
manifest
merscov
infect
emerg
novel
coronaviru
merscov
come
decad
appear
first
highli
pathogen
coronaviru
sarscov
suggest
coronavirus
may
repres
continu
longterm
threat
human
health
sarscov
merscov
believ
origin
bat
sinc
merscovspecif
antibodi
rna
fragment
detect
camel
saudi
arabia
egypt
tunisia
nigeria
kenya
dromedari
camel
middl
east
africa
consid
intermedi
transmitt
merscov
bat
human
importantli
yang
et
al
recent
examin
crossspeci
transmiss
bat
coronaviru
genet
relat
merscov
found
also
use
cellular
receptor
prefer
bat
human
merscov
prefer
human
bat
result
suggest
merscov
adapt
human
gain
entri
host
cell
sinc
bat
natur
host
wide
rang
coronavirus
risk
pose
crossspeci
transmiss
zoonot
coronavirus
human
infect
must
never
underestim
although
emerg
highli
pathogen
merscov
highlight
urgent
need
potent
therapeut
prophylact
agent
approv
antivir
treatment
human
coronaviru
infect
current
avail
recent
tremend
effort
made
search
effect
antimerscov
agent
number
antivir
agent
identifi
exampl
compound
inhibitori
activ
low
micromolar
rang
merscov
replic
cell
cultur
identifi
librari
fdaapprov
drug
falzarano
et
al
also
report
rhesu
macaqu
treat
cocktail
ribavirin
nucleosid
analog
exhibit
reduc
merscov
replic
improv
clinic
outcom
interestingli
lu
et
al
also
found
synthes
peptid
deriv
domain
merscov
spike
protein
could
specif
bind
domain
viral
spike
protein
block
viral
fusion
core
format
result
inhibit
merscov
replic
spike
proteinmedi
cellecel
fusion
optim
improv
inhibitori
activ
analog
potenti
develop
effect
viral
fusion
inhibitor
treatment
merscov
mab
enjoy
signific
clinic
success
use
effect
treatment
number
diseas
particular
cancer
immun
disord
although
synagi
palivizumab
human
mab
respiratori
syncyti
viru
still
mab
approv
fda
clinic
use
viral
diseas
number
antivir
mab
develop
recent
year
clinic
develop
recent
exampl
human
mab
made
histori
first
mab
administ
compassion
basi
human
expos
hendra
viru
base
efficaci
vitro
vivo
recent
zmapp
cocktail
three
mab
show
promis
result
administ
rhesu
monkey
infect
ebola
viru
administ
sever
ebola
patient
broadli
protect
antibodi
influenza
virus
also
test
clinic
trial
sar
outbreak
neutral
antibodi
detect
sar
patient
well
anim
infect
viru
antibodi
also
protect
uninfect
anim
sarscov
infect
specif
passiv
transfer
immun
serum
mice
prevent
viru
replic
lower
respiratori
tract
follow
intranas
viru
challeng
thu
vast
effort
devot
develop
mab
neutral
viru
potenti
treatment
prevent
sarscov
infect
gener
mechan
neutral
mab
thoroughli
review
elsewher
gener
neutral
antibodi
sarscov
isol
memori
bcell
repertoir
patient
recov
sarscov
infect
gener
transgen
mice
human
immunoglobulin
gene
immun
recombin
sarscov
glycoprotein
identifi
nonimmun
human
antibodi
librari
construct
b
lymphocyt
healthi
donor
prophylact
therapeut
efficaci
human
mab
demonstr
mice
ferret
model
sarscov
infect
neutral
antibodi
target
receptor
bind
domain
rbd
sarscov
glycoprotein
suggest
possibl
mechan
neutral
prevent
viru
attach
receptor
antibodi
recogn
epitop
domain
glycoprotein
suggest
mechan
could
also
involv
inhibit
sarscov
infect
includ
steric
hindranc
indirectli
prevent
viru
attach
antibodi
fcmediat
effector
function
exampl
antibodydepend
cellular
cytotox
adcc
sinc
sar
epidem
contain
juli
clinic
develop
abovement
antibodi
target
sarscov
pursu
fortun
wealth
knowledg
accumul
experi
manag
sar
outbreak
therapeut
potenti
coronavirustarget
antibodi
well
recogn
novel
coronaviru
merscov
emerg
saudi
arabia
bodi
knowledg
allow
develop
effect
respons
threat
mer
unpreced
pace
first
found
rbd
merscov
glycoprotein
capabl
induc
signific
neutral
antibodi
respons
mice
thu
neutral
mous
mab
could
develop
block
merscov
entri
human
cell
exampl
du
et
al
gener
neutral
mab
immun
mice
recombin
merscov
fuse
fc
april
three
studi
conduct
separ
laboratori
around
world
report
develop
fulli
human
neutral
mab
merscov
noteworthi
mab
target
rbd
merscov
glycoprotein
identifi
nonimmun
human
antibodi
librari
specif
among
antibodi
three
highli
potent
mab
identifi
larg
phagedisplay
antibodi
fab
librari
recent
gener
use
b
cell
blood
healthi
donor
librari
pan
recombin
merscov
rbd
enrich
high
affin
binder
three
identifi
mab
deriv
vh
gene
sourc
mani
antivir
antibodi
exhibit
except
potent
activ
neutral
pseudotyp
merscov
inhibitori
concentr
ic
rang
mgml
notabl
potent
mab
inhibit
pan
perform
sequenti
use
merscov
spikecontain
paramagnet
proteoliposom
merscov
glycoproteinexpress
cell
antigen
panel
scfv
identifi
express
scfvfc
format
neutral
activ
pseudotyp
merscov
cell
well
live
merscov
infect
vero
cell
measur
potent
antibodi
neutral
live
merscov
plaqu
reduct
neutral
test
ic
mgml
mgml
scfvfc
igg
format
respect
although
abovement
human
mab
exhibit
potent
neutral
activ
merscov
infect
vitro
evalu
efficaci
anim
model
infect
still
necessari
develop
therapeut
prophylact
agent
howev
unlik
sarscov
effect
infect
replic
sever
cell
type
human
anim
includ
mice
rhesu
macaqu
merscov
infect
small
laboratori
anim
eg
mice
hamster
ferret
caus
mild
moder
symptom
rhesu
macaqu
thu
effect
stall
research
effort
variat
among
anim
speci
consid
determin
suscept
merscov
infect
thu
zhao
et
al
develop
mous
model
mer
use
adenoviru
express
human
sensit
mice
infect
prior
transduct
adenovir
human
vector
mice
becam
suscept
merscov
infect
method
could
use
rapid
evalu
antim
vaccin
antivir
therapi
howev
whether
infect
mice
treat
inhaledadenoviru
method
underw
diseas
progress
immun
respons
typic
observ
human
remain
unknown
better
model
could
transgen
mous
model
human
gene
integr
genom
recent
falzarano
et
al
found
merscov
infect
marmoset
close
mimic
sever
pneumonia
experienc
peopl
infect
merscov
anim
infect
merscov
develop
progress
sever
pneumonia
lead
euthanasia
anim
extens
lesion
evid
high
viral
load
detect
lung
marmoset
marmoset
amino
acid
sequenc
ident
human
merscov
glycoprotein
bind
region
result
observ
suscept
merscov
infect
result
suggest
marmoset
model
import
advanc
abil
assess
efficaci
intervent
strategi
mer
turn
allow
preclin
evalu
neutral
mab
treatment
merscov
infect
realiz
prevent
therapeut
potenti
neutral
mab
clinic
set
also
necessari
investig
mechan
antibodi
modul
biolog
behavior
merscov
order
explor
mechan
action
human
mab
first
defin
merscov
epitop
recogn
mab
bind
mab
fragment
glycoprotein
measur
expect
mab
bound
fragment
contain
rbd
specif
residu
analyz
mab
bind
seri
alanin
mutant
rbd
found
three
mab
overlap
distinct
bind
site
exampl
residu
import
bind
three
mab
residu
hand
uniqu
bound
turn
potent
neutral
among
three
mab
suggest
residu
may
crucial
interact
henc
import
vaccin
develop
next
found
three
mab
compet
bind
merscov
rbd
also
compet
rbd
bind
solubl
version
consist
neutral
result
slightli
potent
block
bind
rbd
ic
mgml
respect
valu
rang
similar
neutral
activ
mab
pseudotyp
merscov
cell
mgml
result
support
idea
mab
overlap
epitop
neutral
merscov
compet
receptor
bind
use
mutagenesi
data
merscov
rbd
crystal
structur
gener
threedimension
molecular
dock
model
mab
interact
rbd
good
superimposit
mabsrbd
structur
confirm
competit
merscov
receptor
bind
import
mechan
action
mab
neutral
merscov
cell
entri
extens
overlap
mab
epitop
receptor
bind
site
rbd
explain
except
neutral
potenc
mab
similarli
jiang
et
al
also
found
neutral
mab
could
inhibit
bind
solubl
rbd
cell
bind
competit
assay
tang
et
al
found
six
mab
could
recogn
least
three
differ
epitop
merscov
rbd
antibodi
could
block
bind
merscov
rbd
inhibit
attach
pseudoviru
cell
could
also
block
antibodi
rbd
bind
taken
togeth
result
suggest
neutral
mechan
abovement
human
mab
despit
recogn
differ
epitop
rbd
occur
block
merscov
bind
cellular
receptor
interestingli
jiang
et
al
also
demonstr
combin
found
recogn
differ
epitop
rbd
result
synergist
neutral
effect
pseudotyp
merscov
emerg
virus
eg
sarslik
merslik
novel
coronavirus
highli
like
continu
pose
seriou
threat
human
health
near
futur
context
prudent
develop
strategi
provid
quick
respons
polyclon
human
immunoglobulin
use
variou
degre
success
viral
diseas
centuri
still
clinic
use
exampl
hepat
hepat
b
cytomegaloviru
rabi
measl
vaccinia
howev
number
toxicityrel
problem
arisen
includ
risk
allerg
reaction
pathogen
transmiss
lottolot
variat
addit
small
portion
total
antibodi
polyclon
prepar
typic
neutral
remaind
ineffect
could
immunogen
even
toxic
limit
could
overcom
use
human
mab
nevertheless
major
obstacl
come
difficulti
gener
highli
potent
neutral
mab
rel
short
amount
time
review
summar
recent
develop
human
neutral
mab
merscov
identifi
differ
laboratori
around
globe
unpreced
pace
improv
antibodi
identif
techniqu
combin
recent
advanc
antibodi
product
technolog
highlight
potenti
human
mab
applic
toward
strategi
design
combat
futur
emerg
virus
diseas
outbreak
set
apart
limit
use
antivir
mab
may
produc
escap
mutant
although
mutat
rate
sarscov
merscov
moder
compar
rna
virus
frequenc
emerg
escap
mutant
underestim
promis
solut
may
lie
use
mab
cocktail
two
mab
target
differ
epitop
mix
mab
cocktail
would
provid
potent
antivir
activ
singl
mab
addit
andor
synergist
effect
also
prevent
escap
variant
mani
virus
includ
sarscov
interestingli
even
though
recent
develop
human
mab
merscov
target
rbd
glycoprotein
recogn
distinct
epitop
discuss
therefor
might
expect
emerg
resist
virus
rbdspecif
mab
would
exert
toll
viru
fit
escap
mutant
could
lower
affin
cellular
receptor
furthermor
jiang
et
al
demonstr
combin
two
human
mab
result
synergist
neutral
effect
pseudotyp
merscov
thu
would
interest
test
combin
avail
mab
would
give
similar
better
synergist
effect
whether
mab
cocktail
could
neutral
mutant
virus
emerg
futur
high
product
cost
substanti
obstacl
commerci
develop
antivir
human
mab
especi
mab
emerg
virus
one
strategi
reduc
overal
cost
develop
except
potent
neutral
mab
result
reduct
dose
requir
achiev
efficaci
could
achiev
develop
human
mab
ultra
high
bind
affin
ration
design
product
target
critic
neutral
site
eg
rbd
exampl
except
potent
mab
bind
merscov
rbd
picomolar
affin
potenc
viru
neutral
ic
also
picomolar
rang
suggest
low
dose
mab
could
clinic
effect
furthermor
recent
progress
antibodi
engin
enabl
gener
effect
antibodybas
therapeut
eg
bispecif
antibodi
antibodydrug
conjug
antibodi
improv
effector
function
antibodydepend
cellmedi
cytotox
adcc
notabl
antibodi
fragment
reduc
size
kda
could
achiev
enhanc
tissu
penetr
well
wider
rang
possibl
target
importantli
requir
much
lower
product
cost
provid
potenti
overcom
fundament
limit
fullsiz
mab
howev
compar
mab
antibodi
fragment
vh
fab
display
greatli
reduc
halfliv
limit
clinic
potenti
recent
gener
novel
fcbase
antibodi
fragment
small
size
kda
good
stabil
solubl
rel
long
vivo
halflif
fuse
vh
result
novel
antibodi
construct
still
solubl
express
escherichia
coli
high
yield
therefor
small
longact
antibodi
potenti
develop
commerci
attract
prophylact
therapeut
antivir
wide
array
indic
fig
threat
emerg
infecti
diseas
sar
mer
emphas
need
fast
versatil
approach
allow
us
rapidli
identifi
effect
antivir
combat
virus
review
recent
success
identifi
fulli
human
neutral
mab
merscov
rapid
identif
antibodi
suggest
possibl
use
nonimmun
human
antibodi
librari
relat
methodolog
quick
respons
emerg
virus
pandem
potenti
mab
despit
develop
differ
laboratori
target
rbd
merscov
glycoprotein
may
similar
mechan
action
ie
block
bind
merscov
cellular
receptor
notabl
human
mab
exhibit
except
potent
neutral
activ
merscov
infect
vitro
wherea
evalu
efficaci
effect
anim
infect
model
like
marmoset
merscov
infect
model
yet
perform
mab
recogn
differ
epitop
merscov
rbd
suggest
mab
cocktail
may
exhibit
potent
antim
activ
base
addit
andor
synergist
effect
also
help
prevent
occurr
viral
escap
mutant
expect
recent
advanc
antibodi
engin
foster
develop
effect
afford
therapeut
prophylact
agent
improv
effector
function
make
antibodydrug
conjug
gener
smallsiz
longact
novel
antibodi
construct
base
human
neutral
mab
